Individualized Therapy of chronic lymphocytic Leukemia

被引：0

作者：

von Tresckow, Julia ^{[1
]}

Hallek, Michael ^{[2
,3
,4
]}

Eichhorst, Barbara ^{[2
,3
]}

机构：

[1] Deutsch CLL Studiengrp, Klin Phase & Phase Studien 2 3, Cologne, Germany

[2] Uniklin Koln, Klin Innere Med 1, Cologne, Germany

[3] Deutsch CLL Studiengrp, Cologne, Germany

[4] Int Working Grp CLL, Cologne, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2018年 / 143卷 / 18期

关键词：

PREVIOUSLY UNTREATED PATIENTS; OPEN-LABEL; PHASE-3; TRIAL; CLL; RITUXIMAB; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; CLASSIFICATION; CHLORAMBUCIL; MULTICENTER;

D O I：

10.1055/a-0550-2286

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Because of the excellent prognosis in early asymptomatic stage of the disease all patients outside clinical trial should undergo watch & wait independently of their individual risk profile. Prognostic markers and scoring systems, as the CLL international prognostic index (CLL-IPI), help predicting the individual prognosis. In advanced stage disease standard frontline therapy in patients without high risk factors is still the combination of chemotherapy and CD20-antibody. However, particularly elderly patients with unfavorable prognostic factors may alternatively be treated with the Btk-inhibitor. Novel targeted agents are the treatment of choice in presence of high risk prognostic factors as well as in most relapsed situations. They are currently tested in currently ongoing trials in frontline. © Georg Thieme Verlag KG, Stuttgart New York.

引用

页码：1318 / 1324

页数：7

共 21 条

[1] [Anonymous], ASCO M ABSTR S
[2] [Anonymous], S3 LEITL DIAGN THER
[3] BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[4] 2-V
[5] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A.
Tedeschi, A.
Barr, P. M.
Robak, T.
Owen, C.
Ghia, P.
Bairey, O.
Hillmen, P.
Bartlett, N. L.
Li, J.
Simpson, D.
Grosicki, S.
Devereux, S.
McCarthy, H.
Coutre, S.
Quach, H.
Gaidano, G.
Maslyak, Z.
Stevens, D. A.
Janssens, A.
Offner, F.
Mayer, J.
O'Dwyer, M.
Hellmann, A.
Schuh, A.
Siddiqi, T.
Polliack, A.
Tam, C. S.
Suri, D.
Cheng, M.
Clow, F.
Styles, L.
James, D. F.
Kipps, T. J.
Keating, Michael
Jen, Jie
Jindra, Pavel
Simkovic, Martin
Braester, Andrei
Ruchlemer, Rosa
Foa, Roberto
Semenzato, Gianpietro
Hawkins, Timothy
Atanasio, Carolina Moreno
Demirkan, Fatih
Kaynar, Leylagul
Pylypenko, Halyna
Fox, Christopher
Thirman, Michael
Campbell, Philip
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) : 2425 - 2437
[6] Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Dreger, Peter
Doehner, Hartmut
Ritgen, Matthias
Boettcher, Sebastian
Busch, Raymonde
Dietrich, Sascha
Bunjes, Donald
Cohen, Sandra
Schubert, Joerg
Hegenbart, Ute
Beelen, Dietrich
Zeis, Matthias
Stadler, Michael
Hasenkamp, Justin
Uharek, Lutz
Scheid, Christof
Humpe, Andreas
Zenz, Thorsten
Winkler, Dirk
Hallek, Michael
Kneba, Michael
Schmitz, Norbert
Stilgenbauer, Stephan
[J]. BLOOD, 2010, 116 (14) : 2438 - 2447
[7] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Eichhorst, Barbara
Fink, Anna-Maria
Bahlo, Jasmin
Busch, Raymonde
Kovacs, Gabor
Maurer, Christian
Lange, Elisabeth
Koeppler, Hubert
Kiehl, Michael
Soekler, Martin
Schlag, Rudolf
Vehling-Kaiser, Ursula
Koechling, Georg
Ploeger, Christoph
Gregor, Michael
Plesner, Torben
Trneny, Marek
Fischer, Kirsten
Doehner, Harmut
Kneba, Michael
Wendtner, Clemens-Martin
Klapper, Wolfram
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Boettcher, Sebastian
Hallek, Michael
[J]. LANCET ONCOLOGY, 2016, 17 (07) : 928 - 942
[8] Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Fischer, Kirsten
Bahlo, Jasmin
Fink, Anna Maria
Goede, Valentin
Herling, Carmen Diana
Cramer, Paula
Langerbeins, Petra
von Tresckow, Julia
Engelke, Anja
Maurer, Christian
Kovacs, Gabor
Herling, Marco
Tausch, Eugen
Kreuzer, Karl-Anton
Eichhorst, Barbara
Boettcher, Sebastian
Seymour, John F.
Ghia, Paolo
Marlton, Paula
Kneba, Michael
Wendtner, Clemens-Martin
Doehner, Hartmut
Stilgenbauer, Stephan
Hallek, Michael
[J]. BLOOD, 2016, 127 (02) : 208 - 215
[9] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, Richard R.
Sharman, Jeff P.
Coutre, Steven E.
Cheson, Bruce D.
Pagel, John M.
Hillmen, Peter
Barrientos, Jacqueline C.
Zelenetz, Andrew D.
Kipps, Thomas J.
Flinn, Ian
Ghia, Paolo
Eradat, Herbert
Ervin, Thomas
Lamanna, Nicole
Coiffier, Bertrand
Pettitt, Andrew R.
Ma, Shuo
Stilgenbauer, Stephan
Cramer, Paula
Aiello, Maria
Johnson, Dave M.
Miller, Langdon L.
Li, Daniel
Jahn, Thomas M.
Dansey, Roger D.
Hallek, Michael
O'Brien, Susan M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) : 997 - 1007
[10] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, Valentin
Fischer, Kirsten
Busch, Raymonde
Engelke, Anja
Eichhorst, Barbara
Wendtner, Clemens M.
Chagorova, Tatiana
de la Serna, Javier
Dilhuydy, Marie-Sarah
Illmer, Thomas
Opat, Stephen
Owen, Carolyn J.
Samoylova, Olga
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Doehner, Hartmut
Langerak, Anton W.
Ritgen, Matthias
Kneba, Michael
Asikanius, Elina
Humphrey, Kathryn
Wenger, Michael
Hallek, Michael
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) : 1101 - 1110

← 1 2 3 →